Theravance Biopharma (TBPH) Total Current Liabilities (2013 - 2026)
Theravance Biopharma (TBPH) posted quarterly Total Current Liabilities of $31.8 million for Q1 2026, up 0.87% year-over-year from $31.5 million in Q1 2025, and down 17.04% quarter-over-quarter from $38.3 million in Q4 2025.
Theravance Biopharma (TBPH) Total Current Liabilities (2013 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has reported Total Current Liabilities for 14 consecutive years, with $31.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities rose 0.87% year-over-year to $31.8 million; the TTM figure through Mar 2026 stood at $31.8 million (up 0.87% YoY), while the FY2025 annual figure was $38.3 million, up 19.38% from the prior year.
- Total Current Liabilities fell to $31.8 million in Q1 2026 per TBPH's latest filing, from $38.3 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $142.1 million in Q3 2022 and bottomed at $21.7 million in Q1 2024.
- Historically, Total Current Liabilities has averaged $37.8 million across 5 years, with a median of $31.5 million in 2025.
- Annual changes were most pronounced in 2023 — Total Current Liabilities plunged 82.15% — and 2025, when it jumped 138.09%.
- Theravance Biopharma's Total Current Liabilities stood at $28.7 million in 2022, then dropped by 13.75% to $24.8 million in 2023, then climbed by 29.55% to $32.1 million in 2024, then advanced by 19.38% to $38.3 million in 2025, then retreated by 17.04% to $31.8 million in 2026.
- Business Quant data shows TBPH's Total Current Liabilities at $31.8 million in Q1 2026, $38.3 million in Q4 2025, and $37.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Theravance Biopharma | 880.59 Mn | 492.93 Mn | - | 30.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 30.77 Mn |
| Mar 31, 2026 | 31.78 Mn |
| Dec 31, 2025 | 38.30 Mn |
| Sep 30, 2025 | 37.41 Mn |
| Jun 30, 2025 | 54.63 Mn |
| Mar 31, 2025 | 31.50 Mn |
| Dec 31, 2024 | 32.09 Mn |
| Sep 30, 2024 | 23.44 Mn |
| Jun 30, 2024 | 22.95 Mn |
| Mar 31, 2024 | 21.66 Mn |
| Dec 31, 2023 | 24.77 Mn |
| Sep 30, 2023 | 25.37 Mn |
| Jun 30, 2023 | 24.55 Mn |
| Mar 31, 2023 | 26.18 Mn |
| Dec 31, 2022 | 28.72 Mn |
| Sep 30, 2022 | 142.13 Mn |
| Jun 30, 2022 | 32.62 Mn |
| Mar 31, 2022 | 44.20 Mn |
| Dec 31, 2021 | 58.59 Mn |
| Sep 30, 2021 | 66.08 Mn |